MStranslate logo
Log In
Lost your password?
Lost Password
Back to login
Search
  • HOME
  • Research
    • Basic Sciences
      • B Cells
    • Conferences
      • AAN
      • ACTRIMS
      • ECTRIMS
      • MS Virtual
    • COVID-19
    • Epstein-Barr virus
    • Genetics
    • Gut Microbiome
    • Hormones
    • Lifestyle
      • Diet
      • Exercise
      • Jelinek Group
      • Vitamin D
    • Medicinal Cannabis
    • Mental Health
    • Progressive MS
    • Remyelination
    • Stem Cells
    • Symptoms
      • Cognition
      • Fatigue
      • Quality of Life
      • Rehabilitation
  • Treatments
    • Alemtuzumab
    • Daclizumab
    • Dimethyl fumarate
    • Fingolimod
    • Interferon-Beta
    • Laquinimod
    • Natalizumab
    • Ocrelizumab
    • Clinical Trials & Studies
      • MIS416
  • Lifestyle
  • Collaborations
    • Dr Sally Shaw
    • Dr Travis Stiles
    • Employment & MS
    • Kriesel Lab
    • MBC@RMH
      • MSBase@MBC
      • PrevANZ
      • Neuroimaging
      • Basic Sciences
      • Ocular Motor
      • Movement Disorders & Rehabilitation
    • MitoQ
    • Multiple Sclerosis Limited
  • Connect
    • Live Research Q&A
  • About MStranslate
    • THE TEAM
    • THE APPROACH
    • VALUES & STANDARDS
  • Contact Us
Breaking
  • Patient Community Day at MSToronto2026
  • The ECTRIMS Podcast at MSToronto2026
  • Antiviral Reverses Disability in Mouse Model of MS
  • Assessing & Monitoring Cognition in MS
  • Potential Changes to MS Treatment Access in Australia
  • MS Auckland Webinar: AHSCT as a Treatment for MS
  • HOME
  • Research
    • Basic Sciences
      • B Cells
    • Conferences
      • AAN
      • ACTRIMS
      • ECTRIMS
      • MS Virtual
    • COVID-19
    • Epstein-Barr virus
    • Genetics
    • Gut Microbiome
    • Hormones
    • Lifestyle
      • Diet
      • Exercise
      • Jelinek Group
      • Vitamin D
    • Medicinal Cannabis
    • Mental Health
    • Progressive MS
    • Remyelination
    • Stem Cells
    • Symptoms
      • Cognition
      • Fatigue
      • Quality of Life
      • Rehabilitation
  • Treatments
    • Alemtuzumab
    • Daclizumab
    • Dimethyl fumarate
    • Fingolimod
    • Interferon-Beta
    • Laquinimod
    • Natalizumab
    • Ocrelizumab
    • Clinical Trials & Studies
      • MIS416
  • Lifestyle
  • Collaborations
    • Dr Sally Shaw
    • Dr Travis Stiles
    • Employment & MS
    • Kriesel Lab
    • MBC@RMH
      • MSBase@MBC
      • PrevANZ
      • Neuroimaging
      • Basic Sciences
      • Ocular Motor
      • Movement Disorders & Rehabilitation
    • MitoQ
    • Multiple Sclerosis Limited
  • Connect
    • Live Research Q&A
  • About MStranslate
    • THE TEAM
    • THE APPROACH
    • VALUES & STANDARDS
  • Contact Us
Panellists at Patient Community Day 2026, held at the conclusion of MSToronto2026, are shown in discussion on stage.

Patient Community Day at MSToronto2026

MStranslate
November 6, 2026
Community, ECTRIMS, Events, Research
The word Toronto is shown displayed in large lettering on the edge of what could be a town square in downtown Toronto.

The ECTRIMS Podcast at MSToronto2026

MStranslate
November 5, 2026
Conferences, ECTRIMS, Research
1 Comment
3D medical illustration of HIV virus cells.

Antiviral Reverses Disability in Mouse Model of MS

MStranslate
September 28, 2026
Research, Treatments
cognition

Assessing & Monitoring Cognition in MS

MStranslate
August 11, 2026
Cognition, Research
News

Potential Changes to MS Treatment Access in Australia

MStranslate
July 2, 2026
Treatments
Ocrevus

Ocrevus and PPMS: Where to from here?

MStranslate
September 10, 2018
Ocrelizumab, Opinion, Treatments
The following is an opinion piece written by MStranslate co-founder, Brett Drummond. Let’s rewind to last March last year…there is worldwide excitement as ocrelizumab (Ocrevus) becomes the first treatment...
ibudilast

Ibudilast Phase 2 Trial Results for Progressive MS

MStranslate
August 30, 2018
Progressive MS, Research, Treatments
Research Summary: Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis What is it? Ibudilast is an anti-inflammatory treatment, which also has effects that protect nerves.  It is thought to offer...
heart disease

Heart Disease Linked To Brain Atrophy In MS

MStranslate
August 15, 2018
Basic Sciences, Lifestyle, Research
2 Comments
Research Summary:  Hypertension and heart disease are associated with development of brain atrophy in multiple sclerosis: a 5-year longitudinal study WHO? This study was performed by researchers at the...
primary progressive MS research

Primary Progressive MS Research: Treatment Outcomes

MStranslate
August 9, 2018
Progressive MS, Research, Treatments
PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS Primary progressive multiple sclerosis (PPMS) is characterised by a steady worsening of disease or accumulation of disability from onset without any lengthy periods of...
blood platelets

Inflammation in the CNS is driven by platelets

MStranslate
July 31, 2018
Basic Sciences, Ocular Motor, Research
1 Comment
RESEARCH SUMMARY:  Platelets Drive Inflammation and Target Gray Matter and the Retina in Autoimmune-Mediated Encephalomyelitis. In this article, we are summarising recent research that has investigated the...
myelin repair microglia

Myelin Repair: Cellular Switch Identified?

MStranslate
July 24, 2018
Basic Sciences, Progressive MS, Remyelination, Research
1 Comment
PROGRESSIVE MULTIPLE SCLEROSIS AND MYELIN REPAIR We have seen an increasing number of powerful new treatments developed recently for relapsing remitting multiple sclerosis.  These treatments work in various...
cause of multiple sclerosis theory

Cause of Multiple Sclerosis: Discovery or Theory?

MStranslate
July 23, 2018
Epstein-Barr virus, Infection, Research
CAUSE OF MULTIPLE SCLEROSIS DISCOVERED? Reports have started appearing online today, which claim that doctors from Harvard T.H Chan School of Public Health and the University of Glasgow believe they have...
cannabis for chronic pain

Cannabis and Chronic Pain: Research Summary

MStranslate
July 19, 2018
Medicinal Cannabis, Research, Treatments
Research Summary: Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study WHO? Research was primarily done by a team at the National...
adjusting to ms

MS: Many Stories – Adjustment to MS

MStranslate
July 2, 2018
Community, MS: Many Stories
1 Comment
My Adjustment to MS Written by Sarah, Auckland, NZ In 2016, I was diagnosed with relapse-remitting multiple sclerosis at the age of 32 after an acute six week period of symptoms from lesions in my brain...
Psychiatric Conditions

Is There Genetic Overlap in MS & Psychiatric Conditions?

MStranslate
June 28, 2018
Genetics, Mental Health, Research, Symptoms
Before I start, I want to take this opportunity to thank our community for the extremely positive feedback received on the last article that debuted our new format for research summaries.  Obviously, we have...
  1. 10
  2. 11
  3. 12
  4. 13
  5. 14
  6. 15
  7. 16

Recent Posts

  • Patient Community Day at MSToronto2026
  • The ECTRIMS Podcast at MSToronto2026
  • Antiviral Reverses Disability in Mouse Model of MS
  • Assessing & Monitoring Cognition in MS
  • Potential Changes to MS Treatment Access in Australia

Recent Comments

  • Patient Community Day at MSToronto2026 on The ECTRIMS Podcast at MSToronto2026
  • MStranslate on Multiple Sclerosis Research In 2026
  • MStranslate on Multiple Sclerosis Research In 2026
  • K on Multiple Sclerosis Research In 2026
  • Mohammad on Multiple Sclerosis Research In 2026

Calendar

November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
« Sep    

Archives

Categories

Posts

  • Patient Community Day at MSToronto2026
  • The ECTRIMS Podcast at MSToronto2026
  • Antiviral Reverses Disability in Mouse Model of MS
  • Assessing & Monitoring Cognition in MS
  • Potential Changes to MS Treatment Access in Australia

Google+

Get social

Copyright 2014-2018 MStranslate. All Rights Reserved. Contact Us
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.